Martina Divoká

A lower dosage of imatinib is sufficient to maintain undetectable disease in patients with chronic myeloid leukemia with long-term low-grade toxicity of the treatment

Edgar Faber, Martina Divoká, Ivana Skoumalová et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2015 · 25 citations

Pharmacy, Pharmacology, Pharmacotherapy +11

Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients

Václava Polívková, Peter Rohoň, Hana Klamová et al. · PLoS ONE · 2016 · 22 citations · Full text

Life Sciences, Hematology, Immunology +14

Imatinib trough plasma levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical setting

Edgar Faber, David Friedecký, Kateřina Mičová et al. · Annals of Hematology · 2012 · 21 citations

Medicine, Hematology, Pharmacokinetics +3

FcγRIIIA receptor genotype does not influence an outcome in patients with follicular lymphoma treated with risk-adapted immunochemotherapy

Vít Procházka, Tomáš Papajík, Jana Gazdová et al. · Neoplasma · 2011 · 21 citations

Life Sciences, Hematology, Immunology +13

High Incidence of Unbalanced Chromosomal Changes in Mantle Cell Lymphoma Detected by Comparative Genomic Hybridization

Marie Jarošová, Tomáš Papajík, Milena Holzerová et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2004 · 19 citations

Life Sciences, Genetics, Oncology +14